A Prospective Study of Obesity, Metabolic Health, and Cancer Mortality
- PMID: 29178569
- PMCID: PMC5739969
- DOI: 10.1002/oby.22067
A Prospective Study of Obesity, Metabolic Health, and Cancer Mortality
Abstract
Objective: This study examined whether metabolic health status is associated with risk of cancer mortality and whether this varies by body mass index (BMI) category.
Methods: A prospective study of 22,514 participants from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort was performed. Metabolically unhealthy status was defined as having three or more of the following: (1) elevated fasting glucose, (2) high triglycerides, (3) dyslipidemia, (4) hypertension, and (5) elevated waist circumference. Participants were categorized into normal weight (BMI 18.5-24.9 kg/m2 ), overweight (BMI 25.0-29.9 kg/m2 ), and obesity (BMI ≥ 30 kg/m2 ) groups. Cox proportional hazards regression was performed to estimate hazards ratios (HRs) and 95% confidence intervals (CIs) for cancer mortality during follow-up.
Results: Among participants with normal weight, participants who were metabolically unhealthy had an increased risk of cancer mortality (HR: 1.65; 95% CI: 1.20-2.26) compared with metabolically healthy participants. The overall mortality risk for participants who were metabolically unhealthy and had normal weight was stronger for obesity-related cancers (HR: 2.40; 95% CI: 1.17-4.91). Compared with participants with normal weight, those who were metabolically healthy and overweight were at a reduced risk of any cancer mortality (adjusted HR: 0.79; 95% CI: 0.63-0.99).
Conclusions: There was an increased risk of overall and obesity-related cancer mortality among metabolically unhealthy participants with normal weight.
© 2017 The Obesity Society.
Conflict of interest statement
Dr. Safford reports the following potential conflicts of interest: Amgen - salary support to study patterns of statin use in Medicare and other large databases; diaDexus - salary support for a research grant on lipids and CHD outcomes; diaDexus - consulting to help with FDA application; NIH, AHRQ - salary support for research grants. Dr. Akinyemiju, Dr. Moore, Dr. Pisu, Dr. Judd, Dr. Goodman, Dr. Shikany, Dr. Howard, and Dr. Gilchrist do not report any related conflicts of interest.
Figures
References
-
- Doleman B, Mills KT, Lim S, Zelhart MD, Gagliardi G. Body mass index and colorectal cancer prognosis: a systematic review and meta-analysis. Tech Coloproctol. 2016;20(8):517–535. - PubMed
MeSH terms
Grants and funding
- T32 CA190194/CA/NCI NIH HHS/United States
- K08 HL096841/HL/NHLBI NIH HHS/United States
- U54 CA118638/CA/NCI NIH HHS/United States
- U54 CA118948/CA/NCI NIH HHS/United States
- K01 TW010271/TW/FIC NIH HHS/United States
- P30 DK079626/DK/NIDDK NIH HHS/United States
- R01 NR012726/NR/NINR NIH HHS/United States
- R25 CA047888/CA/NCI NIH HHS/United States
- R01 HL080477/HL/NHLBI NIH HHS/United States
- UL1 TR001417/TR/NCATS NIH HHS/United States
- KL2 RR025776/RR/NCRR NIH HHS/United States
- U01 NS041588/NS/NINDS NIH HHS/United States
- UL1 RR025777/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
